Warning: The NCBI web site requires JavaScript to function. more...
An official website of the United States government
The .gov means it's official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.
The site is secure. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.
Therapeutic antibodies to ganglioside GD2 evolved from highly selective germline antibodies
PubMed Full text in PMC Similar studies Analyze with GEO2R
Therapeutic antibodies to ganglioside GD2 evolved from highly selective germline antibodies VII
Therapeutic antibodies to ganglioside GD2 evolved from highly selective germline antibodies VI
Therapeutic antibodies to ganglioside GD2 evolved from highly selective germline antibodies V
Therapeutic antibodies to ganglioside GD2 evolved from highly selective germline antibodies IV
Therapeutic antibodies to ganglioside GD2 evolved from highly selective germline antibodies III
Therapeutic antibodies to ganglioside GD2 evolved from highly selective germline antibodies II
Therapeutic antibodies to ganglioside GD2 evolved from highly selective germline antibodies I
Whole-Cell Cancer Vaccines Induce Large Antibody Responses to Carbohydrates and Glycoproteins
A Simple, Inexpensive Strategy for Predicting Potential Beneficial Clinical Responses on Prostate Cancer Vaccine Therapy
PubMed Full text in PMC Similar studies
Determination of ABO blood type for prostate cancer patients
Development of a glycan microarray based method for ABO blood typing
Anti-glycan humoral responses after vaccination with PROSTVAC-VF
Analyze with GEO2R
Post-vaccination serum anti-glycan total Ig antibodies of 113 subjects in a clinical trial of PROSTVAC-VF, a therapeutic cancer vaccine. (Dilution = 1:200)
Baseline serum anti-glycan IgM antibodies of 113 subjects in a clinical trial of PROSTVAC-VF, a therapeutic cancer vaccine. (Dilution = 1:50)
Baseline serum anti-glycan total Ig antibodies of 113 subjects in a clinical trial of PROSTVAC-VF, a therapeutic cancer vaccine. (Dilution = 1:50)
Post-vaccination serum anti-glycan IgG antibodies of 113 subjects in a clinical trial of PROSTVAC-VF, a therapeutic cancer vaccine. (Dilution = 1:50)
Post-vaccination serum anti-glycan total Ig antibodies of 28 subjects in a clinical trial of PROSTVAC-VF, a therapeutic cancer vaccine. (Dilution = 1:200)
Post-vaccination serum anti-glycan total Ig antibodies of 28 subjects in a clinical trial of PROSTVAC-VF, a therapeutic cancer vaccine. (Dilution = 1:50)
Post-vaccination serum anti-glycan IgM antibodies of 28 subjects in a clinical trial of PROSTVAC-VF, a therapeutic cancer vaccine. (Dilution = 1:50)
Filters: Manage Filters
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on